Table 1.
mAb | Isotype | Target |
---|---|---|
Efalizumab (Raptiva®) | hIgG1 | αL |
R7.1 | mIgG1 | αL |
TS1/22 | mIgG1 | αL |
Natalizumab (Tysabri®) | hIgG4 | α4 |
Vedolizumab (Entyvio®) | hIgG1 | α4β7 |
Compound | Class | Target |
---|---|---|
LFA878 | Statin derivative | αL |
BIRT377 | Hydantoin derivative | αL |
XVA143 | Peptidomimetic | αLβ2 |
Lifitegrast (Xiidra®) | Peptidomimetic | αLβ2 |
Firategrast | Peptidomimetic | α4β1/α4β7 |
RO0505376 | Peptidomimetic | α4β1/α4β7 |
Abbreviations: h, human; m, mouse.